Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Moderna hasn't been able to count on its vaccine for growth. On top of that, the company's second approved product -- a respiratory syncytial virus (RSV) vaccine -- brought in lower revenue than ...

GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents ...

Shares of Moderna rose 3.4% on Feb. 14 despite a steep ... by the $15 million in initial sales from its newly approved RSV vaccine, mRESVIA. Additionally, the company implemented cost-cutting ...

Valued at a market cap of $9.6 billion, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that ...

There are two vaccines approved by the FDA -- RotaTeq and Rotarix -- that protect against rotavirus, the most common cause of ...